Main Content

Vaccine Development MVA-MERS-S

The aim of the project funded by CEPI (Coalition for Epidemic preparedness Innovation) is the development and approval of a vaccine against MERS coronavirus based on MVA technology. MVA is an attenuated virus (Modified Vaccinia Virus Ankara) which has been equipped with the surface protein of the MERS coronavirus. The recombinant vector vaccine MVA-MERS-S created in this way is used to generate an immune response against the surface protein of the MERS coronavirus.
The Institute of Virology Marburg is responsible for both preclinical investigations and clinical immune monitoring as part of the project. For this purpose, methods for the detection of a humoral immune response are being developed and validated. Subsequently, the sera of vaccinated volunteers are examined concerning the binding and neutralising antibodies that have been developed. In this way, the immunogenicity of the vaccine candidates can be investigated.

Project Lead:

Michael Klüver

Staff members:

Dirk Becker, Gesche Gerresheim, Verena Krähling, Jolanda Mezzacapo, Pauline Neubecker, BSL-4 Animal Facility

Project Partners:

Funding: